🟢 Neuronetics is trading 37.79% up today after Q2 beat and positive adjusted EBITDA

Neuronetics is trading 37.79% higher at $2.99 after its August 11, 2026, second-quarter results exceeded expectations.

• Revenue reached $41.6 million; adjusted EBITDA turned positive at $0.3 million, while the per-share loss narrowed to $0.05 versus the $0.12 estimate.
• Management narrowed full-year revenue guidance to $160 million–$164 million and raised gross-margin targets to 48%–50%.
• Greenbrook clinic growth drove the quarter despite softer NeuroStar technology revenue, supporting the profitability milestone.